Eton Pharmaceuticals, Inc

(NASDAQ:ETON)

Latest On Eton Pharmaceuticals, Inc (ETON):

Date/Time Type Description Signal Details
2023-05-11 19:30 ESTNewsEton Pharmaceuticals GAAP EPS of -$0.10 beats by $0.04, revenue of $5.3M beats by $0.74MN/A
2023-05-11 19:30 ESTNewsEton Pharmaceuticals, Inc. (ETON) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 04:34 ESTNewsEton Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-20 12:57 ESTNewsEton Pharmaceuticals Has Some Potential As A Speculative PlayN/A
2023-03-17 08:31 ESTNewsEton Pharmaceuticals, Inc. (ETON) Q4 2022 Earnings Call TranscriptN/A
2023-03-16 17:33 ESTNewsEton Pharmaceuticals GAAP EPS of $0.04 beats by $0.03, revenue of $8.5M misses by $0.62MN/A
2023-03-16 02:22 ESTNewsEton Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-03-15 10:56 ESTNewsEton acquires Tulex's pediatric rare disease drug ET-600N/A
2023-01-11 09:58 ESTNewsEton says FDA accepted resubmitted NDA for methanol poisoning candidateN/A
2022-12-18 06:29 ESTNewsEton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease PortfolioN/A
2022-11-11 09:37 ESTNewsEton Pharmaceuticals, Inc. (ETON) Q3 2022 Earnings Call TranscriptN/A
2022-11-10 16:33 ESTNewsEton Pharmaceuticals GAAP EPS of -$0.12, revenue of $3.22MN/A
2022-09-14 04:19 ESTNewsEton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrousN/A
2022-08-17 00:40 ESTNewsEton hits 52-week low on patent infringement ruling over generic Cysteine injectionN/A
2022-08-14 22:42 ESTNewsEton Pharmaceuticals: An Evolving 'Sum Of The Parts' StoryN/A
2022-08-12 18:52 ESTNewsEton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-12 02:08 ESTNewsEton Pharmaceuticals GAAP EPS of -$0.06 misses by $0.09, revenue of $7.4M misses by $0.36MN/A
2022-08-11 09:11 ESTNewsEton Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-18 11:34 ESTNewsEton Pharma jumps 20% on FDA approval of seizure therapyN/A
2022-06-25 01:28 ESTNewsEton Pharmaceuticals sells hospital products to Dr. Reddy’s for up to $50MN/A
2022-05-27 19:52 ESTNewsEton Pharmaceuticals down 10% after hours following partner Complete Response LetterN/A
2022-05-17 06:20 ESTNewsEton Pharmaceuticals (ETON) Investor Presentation - SlideshowN/A
2022-05-13 12:51 ESTNewsEton Pharmaceuticals, Inc.'s (ETON) CEO Sean Brynjelsen on Q1 2021 Results - Earnings Call TranscriptN/A
2022-05-12 17:03 ESTNewsEton Pharmaceuticals GAAP EPS of -$0.21, revenue of $2.18MN/A
2022-05-11 22:56 ESTNewsEton Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-11 20:25 ESTNewsEton Pharma gains on FDA approval for Elcys genericN/A
2022-04-11 20:25 ESTNewsJames Gruber joins Eton Pharmaceuticals as CFON/A
2022-03-17 08:20 ESTNewsEton Pharmaceuticals GAAP EPS of $0.04 misses by $0.01, revenue of $6.09M misses by $1.47MN/A
2022-03-17 08:20 ESTNewsEton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-15 23:30 ESTNewsEton Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-03-14 10:21 ESTNewsEton Pharmaceuticals, XGen launch low blood pressure drug RezipresN/A
2021-11-16 20:12 ESTNewsEton Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-16 20:12 ESTNewsWarning: ETON is at high risk of performing badlyN/A
2021-11-16 00:39 ESTNewsEton Pharmaceuticals in pact with Tolmar to jointly promote ALKINDI SPRINKLEN/A
2021-11-16 00:37 ESTNewsEton Pharmaceuticals EPS misses by $0.10, misses on revenueN/A
2021-11-16 00:37 ESTNewsEton Pharmaceuticals' (ETON) CEO Sean Brynjelsen on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-08 11:19 ESTNewsEton Pharma granted FDA approval for seizure and migraine therapyN/A
2021-10-28 20:59 ESTNewsEton Pharma acquires marketing rights to generic version of CarbagluN/A
2021-09-03 15:13 ESTNewsAnother Look At Eton PharmaceuticalsN/A
2021-08-17 13:01 ESTNewsEton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-16 17:26 ESTNewsEton Pharma urged to address misleading claims linked to Alkindi SprinkleN/A
2021-08-16 17:25 ESTNewsEton Pharmaceuticals EPS beats by $0.06, misses on revenueN/A
2021-08-15 22:48 ESTNewsEton Pharmaceuticals Q2 2021 Earnings PreviewN/A
2021-08-10 03:34 ESTNewsEton shares drop 18% on topiramate FDA action date delayN/A
2021-08-09 07:19 ESTNewsFDA decision on Eton's topiramate delayed to NovemberN/A
2021-08-06 23:12 ESTNewsMVST, MDRX, ETON and GDS among after hours moversN/A
2021-07-21 08:02 ESTNewsFDA declines to approve Eton Pharmaceuticals' methanol poisoning treatmentN/A
2021-07-21 07:47 ESTNewsStocks To Watch: FOMC Takes Center Stage, Hedge Funds Pitch And E3N/A
2021-07-21 07:44 ESTNewsEton Pharma wins FDA approval for RezipresN/A
2021-07-21 07:44 ESTNewsEton Pharmaceuticals acquires U.S. and Canadian rights to ZENEO hydrocortisone autoinjectorN/A

About Eton Pharmaceuticals, Inc (ETON):

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. The company offers Biorphen, a phenylephrine hydrochloride injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. It also develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-203, which is injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101 and ET-104, which are oral liquid product candidates for neurological indications; DS-300 and DS-100, which are injectable product candidates; and ET-105, a lamotrigine for oral suspension. Eton Pharmaceuticals, Inc. was founded in 2017 and is based in Deer Park, Illinois.

ETON Quotes by TradingView

See Advanced Chart

General

  • Name Eton Pharmaceuticals, Inc
  • Symbol ETON
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 17
  • Fiscal Year EndDecember
  • IPO Date2018-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.etonpharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 4320.52
  • Price/Book (Most Recent Quarter) 12.5
  • Enterprise Value Revenue 4656.31
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $0.24
  • Next Year EPS Estimate $0.30
  • Next Quarter EPS Estimate -$0.24
  • Operating Margin -69515%
  • Return on Assets -78%
  • Return on Equity -213%
  • Revenue 39000
  • Earnings Per Share -$3.07
  • Revenue Per Share $0
  • Gross Profit -247000
  • Quarterly Earnings Growth -82.4%
View More

Highlights

  • Market Capitalization 200.63 million
  • EBITDA -15345000
  • PE Ratio -17.77
  • Analyst Target Price $13.5
  • Book Value Per Share $0.64
View More

Share Statistics

  • Shares Outstanding 24.41 million
  • Shares Float 13.73 million
  • % Held by Insiders 2803%
  • % Held by Institutions 29.14%
  • Shares Short 788868
  • Shares Short Prior Month 807494
  • Short Ratio 4.72
  • Short % of Float 5%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.23
  • 52 Week High $10.3
  • 52 Week Low $2.75
  • 50 Day Moving Average 8.8
  • 200 Day Moving Average 8.15
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Eton Pharmaceuticals, Inc (ETON) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Eton Pharmaceuticals, Inc (ETON) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A-$0.32-$0.26-23.08%
2020-09-302020-11-12$-161000-$0.31-$0.25-22.38%
2020-06-302020-08-12$N/A-$0.23-$0.2611.54%
2020-03-312020-05-14$99000-$0.50-$0.22-123.91%
2019-12-312020-03-05$459000-$0.15-$0.2643.03%
2019-09-302019-11-14$N/A-$0.28-$0.25-13.5%
2019-06-302019-08-06$N/A-$0.18-$0.2834.55%
2019-03-312019-05-07$500000-$0.42
2018-12-312019-03-25$N/A-$2.24
2018-09-302018-12-20$N/A-$2.24

Eton Pharmaceuticals, Inc (ETON) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Eton Pharmaceuticals, Inc (ETON) Chart:

ETON chart by TradingView

Eton Pharmaceuticals, Inc (ETON) News:

Below you will find a list of latest news for Eton Pharmaceuticals, Inc (ETON) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Eton Pharmaceuticals, Inc (ETON) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-02-202.50CALL0 0676.76TRUE00
2026-02-2050CALL0 0427.18TRUE00
2026-02-207.59.23CALL0 1288.47TRUE00
2026-02-20105.6CALL0 17163.49TRUE00
2026-02-2012.52.15CALL0 8394.28TRUE00
2026-02-20150.69CALL0 29123.03TRUE00
2026-02-2017.50.25CALL183 63672.61FALSE0.227.33
2026-02-20200.06CALL0 19899.06FALSE00
2026-02-2022.50.3CALL0 7210.52FALSE00
2026-02-20250.2CALL0 53443.68FALSE00
2026-02-20300.37CALL0 23500.63FALSE00
2026-02-202.50PUT0 00FALSE00
2026-02-2050PUT0 01189.84FALSE00
2026-02-207.50PUT0 0816.99FALSE00
2026-02-20100.06PUT10 2175.27FALSE0.060
2026-02-2012.50.9PUT0 1425.14FALSE00
2026-02-20150.4PUT5 24784.91FALSE-0.15-0.27
2026-02-2017.52.7PUT0 37119.51TRUE00
2026-02-20203.11PUT0 10TRUE00
2026-02-2022.50PUT0 00TRUE00
2026-02-20250PUT0 00TRUE00
2026-02-20300PUT0 00TRUE00
2026-03-202.50CALL0 0360.04TRUE00
2026-03-2050CALL0 0224.97TRUE00
2026-03-207.50CALL0 0162.77TRUE00
2026-03-20105.36CALL0 387.55TRUE00
2026-03-2012.53CALL0 7354.47TRUE00
2026-03-20152.15CALL42 10766.06TRUE0.350.19
2026-03-2017.50.59CALL55 154.28FALSE0.590
2026-03-20201.2CALL0 3122.33FALSE00
2026-03-2022.50.6CALL1 18110.12FALSE0.60
2026-03-20250CALL0 0228.38FALSE00
2026-03-20300CALL0 0262.1FALSE00
2026-03-202.50PUT0 01185.18FALSE00
2026-03-2050PUT0 0588.11FALSE00
2026-03-207.50PUT0 0403.97FALSE00
2026-03-20100.15PUT0 9291.34FALSE00
2026-03-2012.50.56PUT0 10223.28FALSE00
2026-03-20150PUT0 0123.25FALSE00
2026-03-2017.50PUT0 083.3TRUE00
2026-03-20200PUT0 066.87TRUE00
2026-03-2022.50PUT0 066.4TRUE00
2026-03-20250PUT0 0115.94TRUE00
2026-03-20300PUT0 0117.64TRUE00
2026-05-152.50CALL0 0222.81TRUE00
2026-05-1550CALL0 0135.82TRUE00
2026-05-157.50CALL0 00TRUE00
2026-05-15106CALL0 962.29TRUE00
2026-05-1512.53.73CALL0 163.63TRUE00
2026-05-15152.5CALL3 47459.51TRUE2.50
2026-05-1517.52.05CALL2 15479.2FALSE0.690.51
2026-05-15200.53CALL0 894.01FALSE00
2026-05-1522.50.78CALL2 3475.98FALSE0.780
2026-05-15251.07CALL0 219106.65FALSE00
2026-05-15300CALL0 0161.37FALSE00
2026-05-15351.1CALL0 1177.48FALSE00
2026-05-152.50PUT0 0752.73FALSE00
2026-05-1550PUT0 0372.53FALSE00
2026-05-157.50PUT0 0256.08FALSE00
2026-05-15100.65PUT0 1184.95FALSE00
2026-05-1512.51.45PUT0 3154.08FALSE00
2026-05-15152.4PUT0 68132.84FALSE00
2026-05-1517.53PUT0 169.78TRUE00
2026-05-15200PUT0 074.83TRUE00
2026-05-1522.50PUT0 064.45TRUE00
2026-05-15250PUT0 065.48TRUE00
2026-05-15300PUT0 00TRUE00
2026-05-15350PUT0 00TRUE00
2026-08-212.50CALL0 093.87TRUE00
2026-08-2150CALL0 085.71TRUE00
2026-08-217.50CALL0 058.92TRUE00
2026-08-21105.13CALL0 161.04TRUE00
2026-08-2112.50CALL0 061.82TRUE00
2026-08-21153.05CALL0 11562.14TRUE00
2026-08-2117.50CALL0 067.57FALSE00
2026-08-21202.1CALL0 2569.51FALSE00
2026-08-2122.51.15CALL0 203113.9FALSE00
2026-08-21251.42CALL0 1115.54FALSE00
2026-08-21300CALL0 0118.62FALSE00
2026-08-212.50PUT0 0531.25FALSE00
2026-08-2150PUT0 0261.77FALSE00
2026-08-217.50PUT0 0180.17FALSE00
2026-08-21100PUT0 0139.21FALSE00
2026-08-2112.50PUT0 0123.12FALSE00
2026-08-21152.85PUT0 272.93FALSE00
2026-08-2117.50PUT0 070.55TRUE00
2026-08-21205.6PUT0 1068.08TRUE00
2026-08-2122.50PUT0 066.93TRUE00
2026-08-21250PUT0 066.63TRUE00
2026-08-21300PUT0 064.12TRUE00

Latest ETON Trades:

Date Shares Price
Jun 13, 2022 5:36 PM EST2$2.885
Jun 13, 2022 5:47 PM EST4$2.885
Jun 13, 2022 6:38 PM EST13$2.9
Jun 13, 2022 7:24 PM EST100$2.9
Jun 13, 2022 7:25 PM EST100$2.86

Eton Pharmaceuticals, Inc (ETON) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220010937/0001493152-20-010937-index.htm
2019-12-10UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1710340/000000000019016252/0000000000-19-016252-index.htm
2020-05-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1710340/000000000020003885/0000000000-20-003885-index.htm
2020-05-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1710340/000000000020004688/0000000000-20-004688-index.htm
2020-08-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1710340/000000000020007104/0000000000-20-007104-index.htm
2018-11-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000089914018000602/0000899140-18-000602-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058316/0001209191-18-058316-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058318/0001209191-18-058318-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058320/0001209191-18-058320-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058321/0001209191-18-058321-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058324/0001209191-18-058324-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058325/0001209191-18-058325-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058821/0001209191-18-058821-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058822/0001209191-18-058822-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058824/0001209191-18-058824-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058825/0001209191-18-058825-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058826/0001209191-18-058826-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919118058827/0001209191-18-058827-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018103/0001209191-19-018103-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018106/0001209191-19-018106-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018109/0001209191-19-018109-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018114/0001209191-19-018114-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018118/0001209191-19-018118-index.htm
2019-03-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119018122/0001209191-19-018122-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119032054/0001209191-19-032054-index.htm
2019-08-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119045498/0001209191-19-045498-index.htm
2019-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000120919119045738/0001209191-19-045738-index.htm
2018-11-08CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1710340/000135445718000454/0001354457-18-000454-index.htm
2017-06-28DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315217007275/0001493152-17-007275-index.htm
2018-11-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315218015806/0001493152-18-015806-index.htm
2018-11-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1710340/000149315218016669/0001493152-18-016669-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315218017722/0001493152-18-017722-index.htm
2018-12-2010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315218017724/0001493152-18-017724-index.htm
2019-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219000907/0001493152-19-000907-index.htm
2019-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219001663/0001493152-19-001663-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315219001718/0001493152-19-001718-index.htm
2019-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219002230/0001493152-19-002230-index.htm
2019-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219003813/0001493152-19-003813-index.htm
2019-03-2510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1710340/000149315219003817/0001493152-19-003817-index.htm
2019-03-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1710340/000149315219004108/0001493152-19-004108-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1710340/000149315219006004/0001493152-19-006004-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1710340/000149315219006005/0001493152-19-006005-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219006515/0001493152-19-006515-index.htm
2019-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315219006526/0001493152-19-006526-index.htm
2019-05-24SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315219008254/0001493152-19-008254-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219009066/0001493152-19-009066-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219009127/0001493152-19-009127-index.htm
2019-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219010573/0001493152-19-010573-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219011467/0001493152-19-011467-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219011725/0001493152-19-011725-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315219011727/0001493152-19-011727-index.htm
2019-08-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219012932/0001493152-19-012932-index.htm
2019-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219015787/0001493152-19-015787-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219017479/0001493152-19-017479-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315219017499/0001493152-19-017499-index.htm
2019-12-02S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000149315219018638/0001493152-19-018638-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219018669/0001493152-19-018669-index.htm
2019-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315219019062/0001493152-19-019062-index.htm
2019-12-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1710340/000149315219019077/0001493152-19-019077-index.htm
2020-01-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220000810/0001493152-20-000810-index.htm
2020-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220001575/0001493152-20-001575-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220002532/0001493152-20-002532-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220002695/0001493152-20-002695-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1710340/000149315220003451/0001493152-20-003451-index.htm
2020-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220003486/0001493152-20-003486-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004052/0001493152-20-004052-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004053/0001493152-20-004053-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004056/0001493152-20-004056-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004058/0001493152-20-004058-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004059/0001493152-20-004059-index.htm
2020-03-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004062/0001493152-20-004062-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004113/0001493152-20-004113-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220004191/0001493152-20-004191-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220005035/0001493152-20-005035-index.htm
2020-03-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220005038/0001493152-20-005038-index.htm
2020-04-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220005927/0001493152-20-005927-index.htm
2020-04-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220005929/0001493152-20-005929-index.htm
2020-04-08DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220006039/0001493152-20-006039-index.htm
2020-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220006934/0001493152-20-006934-index.htm
2020-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1710340/000149315220006939/0001493152-20-006939-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220007595/0001493152-20-007595-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220007843/0001493152-20-007843-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220007957/0001493152-20-007957-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220008752/0001493152-20-008752-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220008763/0001493152-20-008763-index.htm
2020-05-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1710340/000149315220009223/0001493152-20-009223-index.htm
2020-05-2110-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1710340/000149315220009627/0001493152-20-009627-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220010937/0001493152-20-010937-index.htm
2020-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220014011/0001493152-20-014011-index.htm
2020-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220014213/0001493152-20-014213-index.htm
2020-07-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000149315220014330/0001493152-20-014330-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220014335/0001493152-20-014335-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220015198/0001493152-20-015198-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220015303/0001493152-20-015303-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220015336/0001493152-20-015336-index.htm
2020-08-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1710340/000149315220016594/0001493152-20-016594-index.htm
2020-08-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220016975/0001493152-20-016975-index.htm
2020-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220017873/0001493152-20-017873-index.htm
2020-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220018322/0001493152-20-018322-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220018576/0001493152-20-018576-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019035/0001493152-20-019035-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019121/0001493152-20-019121-index.htm
2020-10-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220019347/0001493152-20-019347-index.htm
2020-10-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019406/0001493152-20-019406-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019467/0001493152-20-019467-index.htm
2020-10-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1710340/000149315220019503/0001493152-20-019503-index.htm
2020-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019583/0001493152-20-019583-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1710340/000149315220019587/0001493152-20-019587-index.htm
2018-03-20DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1710340/000161577418002013/0001615774-18-002013-index.htm
2018-06-28DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1710340/000161577418005879/0001615774-18-005879-index.htm
2018-08-10S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418007833/0001615774-18-007833-index.htm
2018-09-25S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418009956/0001615774-18-009956-index.htm
2018-09-28FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1710340/000161577418010167/0001615774-18-010167-index.htm
2018-10-18S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418011027/0001615774-18-011027-index.htm
2018-10-31S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418011677/0001615774-18-011677-index.htm
2018-11-05S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1710340/000161577418012090/0001615774-18-012090-index.htm
2018-11-088-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1710340/000161577418012296/0001615774-18-012296-index.htm
2018-11-13424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1710340/000161577418012575/0001615774-18-012575-index.htm
2018-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1710340/000161577418013052/0001615774-18-013052-index.htm
2018-11-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1710340/000161577418013060/0001615774-18-013060-index.htm
2018-11-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1710340/999999999518002850/9999999995-18-002850-index.htm
2019-12-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1710340/999999999519002824/9999999995-19-002824-index.htm
2020-08-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1710340/999999999520002245/9999999995-20-002245-index.htm
2018-11-09CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1710340/999999999718008960/9999999997-18-008960-index.htm

Eton Pharmaceuticals, Inc (ETON) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eton Pharmaceuticals, Inc (ETON). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2803%
Institutional Ownership: 2914%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-11-15MARK L BAUMDirectorBuy10,000.006.0060,000.0010,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058821/0001209191-18-058821-index.htm
2018-11-15SEAN BRYNJELSENPresident & CEOBuy10,000.006.0060,000.001,010,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058826/0001209191-18-058826-index.htm
2019-05-20SEAN BRYNJELSENPresident & CEOBuy1,400.007.7810,894.801,011,400.00https://www.sec.gov/Archives/edgar/data/1710340/000120919119032054/0001209191-19-032054-index.htm
2019-05-21SEAN BRYNJELSENPresident & CEOBuy8,600.007.9668,431.061,020,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919119032054/0001209191-19-032054-index.htm
2019-08-13SEAN BRYNJELSENPresident & CEOBuy5,000.006.1530,750.001,025,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919119045738/0001209191-19-045738-index.htm
2020-10-16Opaleye Management Inc.10% Share HolderBuy15,000.007.00105,000.00155,000.00https://www.sec.gov/Archives/edgar/data/1710340/000149315220019587/0001493152-20-019587-index.htm
2020-10-16Opaleye Management Inc.10% Share HolderBuy385,000.007.002,695,000.003,885,000.00https://www.sec.gov/Archives/edgar/data/1710340/000149315220019587/0001493152-20-019587-index.htm
2018-11-15William Wilson TroutmanCFO, Treasurer & SecretaryBuy5,000.006.0030,000.005,000.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058822/0001209191-18-058822-index.htm
2018-11-15NORBERT G RIEDELDirectorBuy5,000.006.0030,000.0059,745.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058824/0001209191-18-058824-index.htm
2018-11-15PAUL V MAIERDirectorBuy5,000.006.0030,000.0059,745.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058825/0001209191-18-058825-index.htm
2018-11-15CHARLES J CASAMENTODirectorBuy5,000.006.0030,000.0068,420.00https://www.sec.gov/Archives/edgar/data/1710340/000120919118058827/0001209191-18-058827-index.htm
2019-08-09CHARLES J CASAMENTODirectorBuy3,500.006.1121,369.9571,920.00https://www.sec.gov/Archives/edgar/data/1710340/000120919119045498/0001209191-19-045498-index.htm